Skip to main content
SpringerLink
Log in

A randomized trial of chemotherapy (L-PAM vs CMF) and irradiation for node positive breast cancer

Eleven year follow-up of a Piedmont Oncology Association trial

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

158 evaluable patients with stage II, lymph node positive, carcinoma of the breast were randomized to adjuvant therapy with either melphalan (L-PAM) or cyclophosphamide, methotrexate, and fluorouracil (CMF) after mastectomy. In addition, patients were randomized to be treated with or without post-operative irradiation therapy (RT) in addition to their chemotherapy. At a median follow-up time of 11 years, there is no difference in time to relapse (P=0.69) or survival (P=0.55) among the four treatment groups. Multivariate analysis including treatment arm, age, race, tumor size, histologic type, performance status, time to onset of treatment, menopausal status, and number of positive nodes, revealed that only the number of positive nodes (<4 vs ≥ 4) was related to disease-free and overall survival. Ten year relapse-free survival for patients with <4 positive nodes compared to those with ≥4 positive nodes was 63% versus 30%, and overall survival 63% versus 41%, respectively. Patients who received post-operative radiation therapy had significantly less local recurrence than those treated with chemotherapy alone (P=0.03) but without improvement in relapse-free or overall survival. In this trial, post-operative radiation therapy when added to chemotherapy decreased the risk of local recurrence without adverse effects on survival. Treatment outcome was not influenced by chemotherapy regimen, but differences may have been obscured by the small sample size.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, Redmond C, Zellen M, Band P, Katrych DL, Wolmark N, Fisher ER: L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. N Engl J Med 292: 117–123, 1975

    PubMed  Google Scholar 

  2. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294: 405–410, 1976

    PubMed  Google Scholar 

  3. Recht A, Hayes DF: Local recurrence. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases. Lippincott, Philadelphia, 1987, pp 508–524

    Google Scholar 

  4. Beadle GF, Harris JR: The role of post-operative radiotherapy in the treatment of operable breast cancer. [Review]. Breast Cancer Res Treat 4: 159–168, 1984

    Article  PubMed  Google Scholar 

  5. Cuzick J, Stewart H, Peto R, Baum M, Fisher B, Host H, Lythgoe JP, Ribeiro G, Scheurlen H, Wallgren A: Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep 71: 15–29, 1987

    PubMed  Google Scholar 

  6. Cooper MR, Rhyne AL, Muss HB, Ferree C, Richards F, White DR, Stuart JJ, Jackson DV, Howard V, Shore A, Spurr CL: A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancer. Cancer 47: 2833–2839, 1981

    PubMed  Google Scholar 

  7. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958

    Google Scholar 

  8. Cox DR: Regression models and life tables (with discussion). J Royal Stat Soc 34: 187–220, 1972

    Google Scholar 

  9. Canellos GP, Pocock SJ, Taylor SG, Sears ME, Klaasen DJ, Band PR: Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer 38: 1882–1886, 1976

    PubMed  Google Scholar 

  10. Henderson IC: Adjuvant systemic therapy for early breast cancer. Curr Probl Cancer 11: 127–207, 1987

    Google Scholar 

  11. Rivkin SE, Green S, Metch B, Glucksberg H, Gad-el-Mawla N, Constanzi JJ, Hoogstraten B, Athens J, Maloney T, Osborne CK, Vaughn CB: Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study. J Clin Oncol 7: 1229–1238, 1989

    PubMed  Google Scholar 

  12. Fisher B, Glass A, Redmond C, Fisher ER, Barton B, Such E, Carbone P, Economou S, Foster R, Frelick R, Lerner H, Levitt M, Margolese R, MacFarlane J, Plotkin D, Shibata H, Volk H: L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. An update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU). Cancer 39: 2883–2093, 1977

    PubMed  Google Scholar 

  13. Fisher B, Fisher ER, Redmond C: A brief overview of findings from NSABP trials of adjuvant therapy. Recent Results Cancer Res 96: 55–65, 1984

    PubMed  Google Scholar 

  14. Bonadonna G: Conceptual and practical advances in the management of breast cancer. J Clin Oncol 7: 1380–1397, 1989

    PubMed  Google Scholar 

  15. Bonadonna G, Rossi A, Valagussa P, Banfi A, Veronesi U: The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance. Cancer 39: 2904–2915, 1977

    PubMed  Google Scholar 

  16. Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U: Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1: 2–10, 1983

    PubMed  Google Scholar 

  17. Bonadonna G, Valagussa P, Rossi A, Rossi A, Tancini G, Brambilla C, Zambetti M, Veronesi U: Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5: 95–115, 1985

    Article  PubMed  Google Scholar 

  18. Fisher B, Redmond C, Fisher ER, Wolmark N: Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience. Natl Cancer Inst Monogr 35–43, 1986

  19. Jones SE, Moon TE, Bonadonna G, Valagussa P, Rivkin S, Buzdar A, Montague E, Powles T: Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Amer J Clin Oncol 10: 387–395, 1987

    Google Scholar 

  20. Fisher B, Redmond C, Dimitrov NV, Bowman D, Legault-Poisson S, Wickerham DL, Wolmark N, Fisher ER, Margolese R, Sutherland C, Glass A, Foster R, Caplan R, and others: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 320: 473–478, 1989

    PubMed  Google Scholar 

  21. Griem KL, Henderson IC, Gelman R, Ascoli D, Silver B, Recht A, Goodman RL, Hellman S, Harris JR: The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J Clin Oncol 5: 1546–1555, 1987

    PubMed  Google Scholar 

  22. Fowble B, Gray R, Gilchrist K, Goodman RL, Taylor S, Tormey DC: Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol 6: 1107–1117, 1988

    PubMed  Google Scholar 

  23. Overgaard M, Christensen JJ, Johansen H, Nybo-Rasmusen A, Rose C, van der Kooy P, Panduro J, Laursen F, Kjaer M, Sorensen NE, Gadeberg CC, Hjelm-Hansen M, Overgaard J, Andersen KW, Zedeler K: Evaluation of radiotherapy in high-risk breast cancer patients: Report from the Danish breast cancer cooperative group trial (DBCG 82) trial. Int J Radiat Oncol Biol Phys 19: 1121–1124, 1990

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bowman Gray School of Medicine, From the Cancer Center of Wake Forest University, Winston-Salem, N.C., USA

    Hyman B. Muss, M. Robert Cooper, Joni K. Brockschmidt, Carolyn Ferree, Frederick Richards II, Douglas R. White, Don V. Jackson & Charles L. Spurr

Authors
  1. Hyman B. Muss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Robert Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joni K. Brockschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carolyn Ferree
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frederick Richards II
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Douglas R. White
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Don V. Jackson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Charles L. Spurr
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muss, H.B., Cooper, M.R., Brockschmidt, J.K. et al. A randomized trial of chemotherapy (L-PAM vs CMF) and irradiation for node positive breast cancer. Breast Cancer Res Tr 19, 77–84 (1991). https://doi.org/10.1007/BF01980937

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01980937

Key words

Search

Navigation